CONNECTIVE TISSUE DISORDERS

Hereditary Connective Tissue Disorders — overlapping conditions with different aortic surgery thresholds, where the specific gene determines whether prophylactic aortic repair is needed at 5.0cm, 4.5cm, 4.2cm, or 4.0cm — a difference measured in millimeters but counted in lives.

Whole genome sequencing evaluates FBN1, TGFBR1/2, SMAD3, COL3A1, COL5A1, FLNA, and all additional connective tissue genes — providing the gene-specific aortic surveillance protocol that no clinical assessment alone can determine.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Hereditary Connective Tissue Disorders — Comprehensive

Hereditary connective tissue disorders (HCTDs) are a group of genetically distinct conditions sharing features of joint hypermobility, skin hyperextensibility, and vascular fragility — but with critically different aortic and vascular risk profiles. The major conditions include Marfan syndrome (FBN1), Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3), vascular Ehlers-Danlos syndrome (COL3A1), classical EDS (COL5A1, COL5A2), and others. These conditions affect approximately 1 in 3,000-5,000 people collectively.

The aortic dissection risk — the primary life-threatening complication — varies dramatically by gene. Marfan syndrome (FBN1) has a prophylactic aortic root replacement threshold of 5.0cm in adults without additional risk factors. Loeys-Dietz syndrome (TGFBR1/TGFBR2) has a lower threshold of 4.0-4.5cm because aortic dissection frequently occurs at smaller aortic diameters than Marfan. Vascular EDS (COL3A1) causes arterial rupture without preceding aneurysmal dilation — rupture occurs in normal-caliber arteries, requiring a fundamentally different surveillance strategy. These gene-specific aortic management differences directly affect survival.

Clinical overlap between HCTDs — tall stature, joint hypermobility, aortic root dilation, mitral valve prolapse, skin striae — makes clinical diagnosis unreliable without molecular testing. A patient clinically diagnosed with Marfan syndrome may actually have Loeys-Dietz syndrome (requiring more aggressive aortic surveillance and a lower surgical threshold) or familial thoracic aortic aneurysm (FTAAD, with different genetic counseling implications). The 2010 revised Ghent criteria for Marfan syndrome explicitly incorporate molecular FBN1 testing for diagnostic confirmation. All major aortic management guidelines now recommend gene-specific management.

Vascular EDS (COL3A1) causes arterial rupture without prior aneurysmal dilation — standard aortic diameter surveillance DOES NOT WORK for this condition. Management requires avoiding invasive vascular procedures whenever possible. Gene-specific diagnosis is life-saving.

Gene locus
FBN1 (15q21.1), TGFBR1 (9q22.33), TGFBR2 (3p24.1), SMAD3 (15q22.33), COL3A1 (2q32.2), ACTA2 (10q23.31)

Aortic surgery thresholds differ by 1+ centimeters between HCTDs. Operating at 5.0cm is appropriate for Marfan but dangerously late for Loeys-Dietz. Molecular diagnosis provides the gene-specific threshold.

Loeys-Dietz aortas dissect at smaller diameters than Marfan — the wrong surgical threshold kills patients

Multiple studies document that TGFBR1/TGFBR2 patients experience aortic dissection at root diameters of 4.0-4.5cm — well below the 5.0cm Marfan threshold. A patient clinically diagnosed as Marfan who actually has Loeys-Dietz will be monitored with a 5.0cm surgical threshold, placing them at risk for dissection before reaching the trigger for prophylactic surgery. WGS identifies the specific gene, enabling immediately application of the correct gene-specific aortic management protocol.

25% of thoracic aortic aneurysm patients have no Marfan features — familial TAAD genes require screening

Familial thoracic aortic aneurysm and dissection (FTAAD) is caused by variants in ACTA2, MYH11, PRKG1, MYLK, LOX, and MAT2A — producing aortic disease without the skeletal or ocular features of Marfan syndrome. These patients may appear clinically 'normal' until their aorta dissects. Family screening in FTAAD is critical: first-degree relatives of confirmed FTAAD patients have a 50% chance of carrying the variant and should have baseline and serial aortic imaging. WGS identifies FTAAD genes that are not tested on standard Marfan panels.

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks